BioSpace News Archive

Hope Medicine Inc. announced recently that the company has completed a Phase Ib study, “An Open-Label Study, to Evaluate Safety, Tolerability, and Efficacy in Male and Female with Androgenetic Alopecia Treated with HMI-115 over a 24-Week Treatment Period”.

Arcutis Biotherapeutics, Inc. announced new individual patient response data showing the vast majority of individuals treated with investigational roflumilast cream 0.15% had a measurable improvement in Eczema Area and Severity Index in 4 weeks.

Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, will present new data across its dermatologic portfolio of commercially available and pipeline gene expression profile tests at the 2024 Winter Clinical Dermatology Conference - Hawaii, being held Jan. 12-17 in Honolulu, Hawaii.

Arcutis Biotherapeutics, Inc. announced a new subgroup analysis highlighting that adults and adolescents with seborrheic dermatitis who are contraindicated, intolerant, or unresponsive to topical steroids were 3.5 times more likely to achieve IGA Success with ZORYVE® topical foam, 0.3%, compared to vehicle i.